261 related articles for article (PubMed ID: 9063690)
21. Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs.
Yamakuni H; Sawai H; Maeda Y; Imazumi K; Sakuma H; Matsuo M; Mutoh S; Seki J
J Pharmacol Exp Ther; 2000 Mar; 292(3):1002-7. PubMed ID: 10688616
[TBL] [Abstract][Full Text] [Related]
22. Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils.
Bristow LJ; Young L
Eur J Pharmacol; 1994 Mar; 253(3):245-52. PubMed ID: 7515350
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of PD 154075, a tachykinin NK1 receptor antagonist, in a rat model of postoperative pain.
Gonzalez MI; Field MJ; Holloman EF; Hughes J; Oles RJ; Singh L
Eur J Pharmacol; 1998 Mar; 344(2-3):115-20. PubMed ID: 9600644
[TBL] [Abstract][Full Text] [Related]
24. The actions of ondansetron and dexamethasone to antagonise cisplatin-induced emesis in the ferret.
Rudd JA; Naylor RJ
Eur J Pharmacol; 1997 Mar; 322(1):79-82. PubMed ID: 9088874
[TBL] [Abstract][Full Text] [Related]
25. Effects of HSP-117, a novel tachykinin NK1-receptor antagonist, on cisplatin-induced pica as a new evaluation of delayed emesis in rats.
Saeki M; Sakai M; Saito R; Kubota H; Ariumi H; Takano Y; Yamatodani A; Kamiya H
Jpn J Pharmacol; 2001 Jul; 86(3):359-62. PubMed ID: 11488439
[TBL] [Abstract][Full Text] [Related]
26. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
[TBL] [Abstract][Full Text] [Related]
27. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret.
Tattersall FD; Rycroft W; Hargreaves RJ; Hill RG
Eur J Pharmacol; 1993 Nov; 250(1):R5-6. PubMed ID: 8119305
[TBL] [Abstract][Full Text] [Related]
28. Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist.
Grélot L; Dapzol J; Estève E; Frugière A; Bianchi AL; Sheldrick RL; Gardner CJ; Ward P
Br J Pharmacol; 1998 Aug; 124(8):1643-50. PubMed ID: 9756379
[TBL] [Abstract][Full Text] [Related]
29. Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets.
Gonsalves S; Watson J; Ashton C
Eur J Pharmacol; 1996 Jun; 305(1-3):181-5. PubMed ID: 8813551
[TBL] [Abstract][Full Text] [Related]
30. Antiemetic effects of sendide, a peptide tachykinin NK1 receptor antagonist, in the ferret.
Minami M; Endo T; Kikuchi K; Ihira E; Hirafuji M; Hamaue N; Monma Y; Sakurada T; Tan-no K; Kisara K
Eur J Pharmacol; 1998 Dec; 363(1):49-55. PubMed ID: 9877081
[TBL] [Abstract][Full Text] [Related]
31. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
Youssefyeh RD; Campbell HF; Airey JE; Klein S; Schnapper M; Powers M; Woodward R; Rodriguez W; Golec S; Studt W
J Med Chem; 1992 Mar; 35(5):903-11. PubMed ID: 1548679
[TBL] [Abstract][Full Text] [Related]
32. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat.
Cellier E; Barbot L; Regoli D; Couture R
Br J Pharmacol; 1997 Oct; 122(4):643-54. PubMed ID: 9375960
[TBL] [Abstract][Full Text] [Related]
34. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity.
Gardner CJ; Armour DR; Beattie DT; Gale JD; Hawcock AB; Kilpatrick GJ; Twissell DJ; Ward P
Regul Pept; 1996 Aug; 65(1):45-53. PubMed ID: 8876035
[TBL] [Abstract][Full Text] [Related]
35. Action of metyrapone and tetracosactrin to modify cisplatin-induced acute and delayed emesis in the ferret.
Sam TS; Kan KK; Ngan MP; Rudd JA; Yeung JH
Eur J Pharmacol; 2003 Apr; 466(1-2):163-8. PubMed ID: 12679153
[TBL] [Abstract][Full Text] [Related]
36. Antiemetic effects of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin- and apomorphine-induced emesis in dogs.
Furukawa TY; Nakayama H; Kikuchi A; Imazumi K; Yamakuni H; Sogabe H; Yamasaki S; Takeshita K; Matsuo M; Manda T; Uchida W
Biol Pharm Bull; 2013; 36(6):974-9. PubMed ID: 23727919
[TBL] [Abstract][Full Text] [Related]
37. Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets.
Yamakuni H; Sawai-Nakayama H; Imazumi K; Maeda Y; Matsuo M; Manda T; Mutoh S
Eur J Pharmacol; 2002 May; 442(3):273-8. PubMed ID: 12065081
[TBL] [Abstract][Full Text] [Related]
38. Comparison of three preclinical models for nausea and vomiting assessment.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617
[TBL] [Abstract][Full Text] [Related]
39. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT₃ receptor antagonists.
Percie du Sert N; Rudd JA; Apfel CC; Andrews PL
Cancer Chemother Pharmacol; 2011 Mar; 67(3):667-86. PubMed ID: 20509026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
